Bio-Connect

Products

Are you looking for life science and diagnostic reagents? We offer one of the most extensive ranges in the Benelux. There are currently more than 5 million products in our webshop, which are manufactured by more than 130 suppliers. This includes both life science and diagnostic reagents. We hope to support your research with everything you need.

85 to 96 of 1.329.952 products
Sort by
Cross-reactivity with Bet v 1 homologous plant allergens
Product group Antibodies
OriGene
ApplicationsNeutralisation/Blocking
  • SizePrice
Modulation of IgE (allergic patients) binding to Bet v 1
Product group Antibodies
OriGene
ApplicationsNeutralisation/Blocking
  • SizePrice
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C.
Product group Antibodies
OriGene
ApplicationsImmunoPrecipitation, ELISA
  • SizePrice
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C.
Product group Antibodies
OriGene
ApplicationsELISA
  • SizePrice
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C.
Product group Antibodies
OriGene
ApplicationsELISA
  • SizePrice
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C.
Product group Antibodies
OriGene
ApplicationsWestern Blot, ELISA
  • SizePrice
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C.
Product group Antibodies
OriGene
ApplicationsELISA
  • SizePrice
Facs staining of in vitro-derived DCs with 214A9.01
Product group Antibodies
OriGene
ApplicationsFlow Cytometry, ImmunoFluorescence
ReactivityHuman
TargetCD1A
  • SizePrice
IHC staining of human lung cancer frozen section with clone 214A9 (DDX0080)
Product group Antibodies
OriGene
ApplicationsFlow Cytometry, ImmunoFluorescence
ReactivityHuman
TargetCD1A
  • SizePrice
Facs staining of in vitro-derived DCs with 214A9.01
Product group Antibodies
OriGene
ApplicationsImmunoFluorescence
ReactivityHuman
TargetCD1A
  • SizePrice
Facs staining of in vitro-derived DCs with 214A9.01
Product group Antibodies
OriGene
ApplicationsFlow Cytometry, ImmunoHistoChemistry
ReactivityHuman
TargetCD1A
  • SizePrice
Human skin cryosection stained with 214A9
Product group Antibodies
OriGene
ApplicationsFlow Cytometry, Western Blot, ImmunoHistoChemistry
ReactivityHuman
TargetCD1A
  • SizePrice